Kornimate/medical-research-clean huggingface dataset:
clinical impact of 16s rdna pcr

Conditions: Bacterial Infections

Summary: the main objective of this study is to evaluate the impact of a positive 16s rdna pcr in various sites on patient's management. the secondary objectives of the protocol are: * to evaluate bacterial identification performance * to evaluate the effect of previous antibiotic therapy * to analyze the management of discordant results between 16s pcr and culture identification


Eligibility criteria:
inclusion criteria: * patients that had a 16s rdna pcr positive result in strasbourg university hospital laboratory from 2014 to 2018 * patients consent for this analysis of their past medical history * legal guardians consent for the analysis of their children's medical history exclusion criteria: * patients who express opposition for this study * incomplete clinical record
repository: evaluation of immunoregulatory cells in hematopoietic stem cell transplant

Conditions: Hematopoietic Stem Cell Transplantation; Graft vs Host Disease

Summary: this is a repository to store blood and stem cell samples for future research.

our hypothesis is that the graft-versus-tumor effect can be enhanced while minimizing the complications of gvhd by determining the qualitative and quantitative changes in t regulatory cells throughout the transplant process. our understanding of this can lead to new treatment strategies and improved clinical therapeutic implications.

Eligibility criteria:
inclusion criteria: * patients 18-70 years old undergoing either autologous transplant or allogeneic transplant for various hematologic conditions exclusion criteria: * patients \ 70 years old undergoing either autologous transplant or allogeneic transplant

Keywords: t-lymphocyte subsets
pseudodrynaria coronana (wall) ching

Conditions: Osteoporosis

Summary: the study to evaluate the clinical effect of "gusuibu" lasts for 3 years. it aims to evaluate its effect on bone density of postmenopausal osteoporosis. besides, its effects on the liver, kidney and the hematological influence will be evaluated, too.

research of the this traditional chinese medicine clinucal, gusuibu, curative effect is plan three years time. the entire studyaims to evaluated the effect of the traditional chinese medicine on postmenpausal osteoporosis as well as the possible side effects on the experimental animal and the human body. all subjects were postmenopausal woman with established osteoporosis.

Eligibility criteria:
inclusion criteria: * postmenopausal osteoporosis exclusion criteria: * insulin dependent diabetes
clinical and stereoradiological comparison of the results after primary cemented total knee arthroplasty inserted with or without the use of a tourniquet

Conditions: Osteoarthritis of the Knee

Summary: the purpose of this study is to investigate if the use of a tourniquet during insertion of a cemented primary total knee arthroplasty will influence clinical and radiological (measured with rsa x-ray technique) outcome.


Eligibility criteria:
inclusion criteria: * clinical diagnosis og osteoarthritis of the knee * patients must be 18 years or older * patients must understand and speak danish * must be able to give signed consent exclusion criteria: * severe medical illness * documented osteoporosis * rheumatoid arthritis * prior surgery in the knee * neuropathy

Keywords: tka rsa tourniquet arthroplasty knee
accelerating delivery of rheumatic heart disease preventive interventions in northern uganda

Conditions: Rheumatic Heart Disease

Summary: the goal of this prospective study is to evaluate the feasibility, sustainability, and public health impact of a district-based program for secondary prevention of rheumatic heart disease (rhd) in uganda.

adunu is a non-randomized experiment, testing a strategy for implementing an evidence-based practice, decentralized rhd preventive services. the objectives of the study are to: objective 1: demonstrate the impact of adunu, using the re-aim framework to assess program reach, effectiveness, adoption, implementation and maintenance. objective 2: estimate the cost-effectiveness and budget impact of adunu. adunu is a public health initiative that will be deployed the uganda ministry of health in partnership with the district health offices (dho) in two districts. the program will be overseen by the technical and quality assurance (taqa). adunu's main components will include a rhd testing program which consists of community and facility based echocardiographic screening of children and young adults and a registry based secondary prophylaxis injections of benzathine penicillin g (bpg) at local health centers iii and ivs in both districts.

Eligibility criteria:
inclusion criteria: * residing in one of two involved districts in uganda * providers at hciiis and hcivs located in one of two involved ugandan districts exclusion criteria: * none
assessing abuse potential of parenteral buprenorphine/naloxone in non-dependent opioid abusers

Conditions: Opioid-Related Disorders

Summary: buprenorphine, a treatment for opioid dependence, can be mixed with another drug, naloxone, to limit abuse potential. parenteral administration (intravenous or intramuscular injection) of buprenorphine/naloxone causes withdrawal symptoms in opioid dependent individuals. however, naloxone does not cause withdrawal symptoms in non-dependent opioid abusers. this study will investigate whether naloxone decreases the opioid agonist effect from injected buprenorphine, hence decreasing the abuse potential of buprenorphine/naloxone, in non-dependent opioid abusers.

naloxone has been combined with buprenorphine to decrease the parenteral abuse potential of buprenorphine in opioid dependent individuals through the mechanism of naloxone-precipitated withdrawal. while naloxone will not precipitate withdrawal in individuals who are not physically dependent on opioids, it is possible naloxone might attenuate buprenorphine's agonist effects, especially if administered parenterally. the purpose of this study is to assess the effect of sublingual (sl) and intramuscular (im) buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers. participants will stay on a research ward and will undergo challenge sessions twice per week. the following conditions will be tested: placebo; im hydromorphone (2 and 4 mg; an opioid agonist positive control condition); sl buprenorphine (4, 8, and 16 mg); im buprenorphine (4, 8, and 16 mg); sl buprenorphine/naloxone(4/1, 8/2, and 16/4 mg); and im buprenorphine/naloxone (4/1, 8/2, and 16/4 mg). during challenge sessions, physiological status will be recorded continuously and tasks assessing psychomotor, subjective, and objective status will be performed repeatedly.

Eligibility criteria:
inclusion criteria: * non-dependent opioid abuser * actively abusing opioids by injection exclusion criteria: * opioid dependence * signs or symptoms of opioid withdrawal, once admitted to residential unit

Keywords: opioid dependence
robotically-assisted minimally-invasive direct coronary artery bypass with stenting, randomized against coronary artery bypass graft surgery

Conditions: Coronary Artery Disease; Multivessel Coronary Artery Disease

Summary: the study objective is to compare standard cabg to a hybrid revascularization strategy (ra-midcab + pci) in patients who have multi-vessel cad and an indication for surgery, but who have a slightly higher risk of post-operative complications.


Eligibility criteria:
inclusion criteria: 1. multi-vessel cad with an indication for revascularization, 2. presence of at least 1 risk factor for increased risk of post-operative death or major complication, * any patient age \> 80, or * any patient with egfr (glomerular filtration rate) \< 50, or * any patient with lvef \< 40%, or * any patient deemed to be "frail" by consulting surgeon. or * patients \> 75 years of age with at least one of the following: * ejection fraction \< 50% * history of prior cva (cerebral vascular accident) 3. coronary artery anatomy appropriate for a robotically-assisted midcab or regular cabg, vessels other than the left anterior descending with lesions amenable to either cabg or pci. exclusion criteria 1. significant left main coronary artery disease, 2. ejection fraction \< 30%, 3. patients with gfr \< 30, 4. patients unable to take dual anti-platelet agents due to high bleeding risk, 5. patients requiring emergent surgery, including patients with hemodynamic instability, 6. patients with anatomy not suitable for a robotically-assisted approach (by ct chest).

Keywords: cabg hybrid coronary revascularization robotically-assisted minimally-invasive direct coronary artery bypass ra-midcab
a study of the patterns of use of etoricoxib in france (mk-0663-148)

Conditions: Osteoarthritis

Summary: this postmarketing study will examine the use of etoricoxib (arcoxia®) in routine clinical practice in france as well as the use of celecoxib (celebrex®).


Eligibility criteria:
inclusion criteria: * treatment-naive, discontinued the previous treatment course of etoricoxib or celecoxib at least 3 months previously or currently receiving continuous treatment with oral etoricoxib or celecoxib * consent to take part in the study * included in his/her physician's client base for at least 1 year exclusion criteria: * unable to receive follow-up over a year * included in an interventional trial

Keywords: pharmacoepidemiological longitudinal observational
are there sleep-related factors that contribute to an increased incidence of pre-eclampsia at altitude?

Conditions: Pre-Eclampsia

Summary: women at altitude have an increased incidence of pre-eclampsia. populations at altitude have a greater incidence of sleep apnea. and women with sleep apnea are at increased risk of developing preeclampsia. this research project will recruit for home sleep testing: healthy pregnant women at altitude (summit county , colorado at 9000 ft.), and women with preeclampsia at altitude, in order to learn whether either sleep apnea or nocturnal hypoxemia is more common or more severe in women with preeclampsia, than in healthy women at altitude. in addition a healthy co-hort of pregnant women will be studied at sea level, to compare to the healthy cohort of pregnant woman in summit county, to learn to degree that this difference in altitude effects the severity of sleep apnea and hypoxemia.

it is known that high altitude increases the risk of preeclampsia and small for gestational age births. our questions are: 1). is sleep apnea during pregnancy more common and/or more severe at altitude? and 2) do the women who develop preeclampsia at altitude have more severe sleep apnea, or worse hypoxemia during sleep, than the women at altitude who do not develop preeclampsia. we will perform watchpat-one home sleep tests (pat = peripheral arterial tonometry) on up to 20 pregnant women in summit county colorado (\>9000 ft.elevation) who develop preeclampsia during pregnancy (soon after diagnosis), and also on up to 20 pregnant healthy women in summit county, and 20 healthy pregnant women in baltimore (at sea level). these healthy pregnant women in summit county and baltimore will be selected from volunteer participants, to best match age, pre-pregnancy bmi, and race with individuals in summit county who are studied with preeclampsia and they will be studied at the gestational timing that matches their summit county preeclampsia matching subject. in addition to the up to 20 healthy pregnant subjects at summit county and 20 in baltimore, who match the preeclampsia subjects, we will recruit up to 20 more in summit county and 20 more in baltimore, to study specifically in the 33rd or 34th gestational week, to improve our ability to evaluate the effects of altitude on sleep apnea, during pregnancy. information on the births, including height and weight and apgar scores will be assessed, in part to see whether sleep apnea during pregnancy affects outcomes. all sleep studies will be scored at the jhh (johns hopkins hospital) bayview sleep lab's center for interdisciplinary sleep research and education.

Eligibility criteria:
inclusion criteria: pregnant, age 18-35, possession of, or availablitiy of using a cell phone. - exclusion criteria: for the control group the following are exclusion criteria: hypertension, known sleep apnea, asthma requiring daily inhaler use, other lung disease, diabetes for the group who are recruited at the time of diagnosis of pre-eclampsia - hypertension is not an exclusion criteria. -

Keywords: pre-eclampsia, altitude, sleep apnea
penetrance of third generation fluoroquinolones in eyes with functioning filtering blebs

Conditions: Cataract

Summary: based on previous results with eyes without filtering blebs, the aqueous concentrations of ofloxacin and levofloxacin will exceed the concentration of ciprofloxacin after either topical or topical plus oral administration.

the purpose of this study is to assay human aqueous for concentrations of ofloxacin, ciprofloxacin and levofloxacin after topical or combined topical and oral administration in eyes with filtering blebs.

Eligibility criteria:
inclusion criteria: * all patients with functioning filtering blebs will be evaluated prospectively for inclusion exclusion criteria: * any subject who is already scheduled to have cataract surgery performed will qualify for participation with the exception of the following exclusion criteria: * ongoing ocular inflammatory disease * bleb leakage - determined by seidel test * suspected infection * known contraindications to use of any of these study medications. * pregnancy

Keywords: cataract aqueous absorption funtioning filtering blebs
laboratory aspirin resistance in diabetics and non-diabetics

Conditions: Drug Resistance

Summary: despite treatment with aspirin a large number of patients suffer a myocardial infarction. it has been speculated that these patients might be "resistant" to aspirin, and studies have indicated that this phenomenon is related to a less favourable prognosis. furthermore, patients with diabetes mellitus have an increased risk of myocardial infarction and other vascular events and, recently, it has been suggested that diabetics do not respond adequately to aspirin. the purpose of this study is to compare the prevalence of "aspirin resistance" in diabetics and non-diabetics. furthermore, patients who suffered a myocardial infarction while being treated with aspirin are included. we hypothesize that the prevalence of "aspirin resistance" will be higher among diabetics compared to other patients and to healthy individuals.

a considerable number of patients suffer acute coronary events despite being treated with antiplatelet therapy such as aspirin. taken together with laboratory findings of a low response to aspirin, the term "aspirin resistance" has been coined. diabetics have an increased risk of suffering ischemic vascular events and, recently, an increased prevalence of "aspirin resistance" was reported in these patients. the purpose of the present study is to compare the aspirin response in diabetics and non-diabetics in a population with angiogram-verified coronary artery disease. furthermore, healthy volunteers and patients who suffered a myocardial infarction while being treated with aspirin are included. eligible patients are identified in the western denmark heart registry.

Eligibility criteria:
inclusion criteria: * ischemic heart disease verified by coronary angiogram (group:"cad") * treatment with aspirin 75 mg/d for at least the previous 7 days(groups: "cad" and "previous myocardial infarction") * type ii diabetes mellitus (\~50% of groups: "cad" and "previous myocardial infarction") * ≥ 1 myocardial infarction more than one year ago while taking daily aspirin ≥ 75 mg/d (group: "previous myocardial infarction"). exclusion criteria: * treatment with nsaids, clopidogrel, ticlopidine, dipyridamole, warfarin or any other drugs known to affect platelet function. * ischemic vascular event within the previous 12 months * revascularization (angioplasty or coronary by-pass graft surgery) within the previous 12 months * intake of nsaids within 1 week of myocardial infarction (group: "previous myocardial infarction"). * platelet count \< 120 x 10\^9/l * previous myocardial infarction (group: "cad"). * not able to give informed consent

Keywords: platelets platelet aggregation drug resistance aspirin diabetes mellitus
risk factors of the revisit of the adult heart failure patients in emergency department siriraj hospital

Conditions: Congestive Heart Failure; Renal Insufficiency

Summary: to identify the risk factors of the revisit of the adult hf patients in emergency department.

because heart failure (hf) is the leading cause of hospitalization and readmission in many hospitals worldwide. identifying the risk factors of these hf patients in emergency department is the important reason for the proper management of the hf patients in the future. and can reduce number of hospitalization and readmission in our hospital.

Eligibility criteria:
inclusion criteria: * patients age from 18 years old * patients who were diagnosed hf by the framingham's criteria10 * patients who were discharged home from emergency department exclusion criteria: * patients age less than 18 years old * patients who not met framingham's criteria, needed hospital admission, were referred to other hospital, and death

Keywords: heart failure revisit emergency room
randomized open investigation determining steroid dose

Conditions: Covid19

Summary: dexamethasone has been approved for the treatment of severe covid-19, but higher doses of steroids may be more effective. the purpose of this research study is to compare the current standard dose of dexamethasone 6 mg to a higher, weight-based dosing (0.2 mg/kg with maximum dose of 20 mg) to determine if it would be more effective against covid-19 pneumonia.

treatment for covid-19 patients with respiratory failure has been vexing, but the use of steroids has shown promise. in a recent randomized control trial, dexamethasone 6 mg once daily showed a modest decrease in mortality among hospitalized covid-19 patients who require oxygen supplementation or invasive mechanical ventilation. other trials have shown that the inflammatory response to covid-19 can be further attenuated at higher dosages of dexamethasone. these higher dosages have not been well studied and have not been directly compared to the current standard dose of dexamethasone 6 mg daily. we propose that a higher dexamethasone dose, equivalent to methylprednisolone 1 mg/kg/day which is routinely used to treat other inflammatory conditions of the lungs, may be more effective than the current standard dose in reducing mortality in covid-19 patients with respiratory failure.

Eligibility criteria:
inclusion criteria: * adults greater or equal than 18 years old * covid-19 infection confirmed by positive pcr test * hypoxemia defined by an oxygen saturation \< 94% or the need for supplemental oxygen exclusion criteria: * corticosteroid use for \> 48h within the past 15 days prior to enrollment * use of steroids with doses higher than the equivalent to dexamethasone 6 mg * use of immunosuppressive drugs * pregnant women * chronic oxygen use * known history of dexamethasone allergy * dnr / dni * patient or proxy cannot consent

Keywords: dexamethasone covid-19 covid pneumonia respiratory failure steroids
a phase i/ii study of mitoxantrone liposome combined with chidamide in relapsed/refractory peripheral t-cell lymphoma

Conditions: Relapsed and Refractory Peripheral T-cell Lymphoma

Summary: peripheral t-cell lymphoma (ptcl) is a highly heterogeneous group of aggressive non-hodgkin lymphoma (nhl) originating from mature thymus t cells.mitoxantrone hydrochloride liposome injection can accelerate the entry of mitoxantrone into cells, reduce the efflux of mitoxantrone, ensure the concentration of intracellular drugs, reverse the drug resistance mechanism, and enhance anti-tumor activity.we will explore the dose-limiting toxicity (dlt) of mitoxantrone hydrochloride liposome injection combined with chidamide in the treatment of relapsed or refractory peripheral t-cell lymphoma, estimate the maximum tolerated dose (mtd) of the combination, and determine the phase ii recommended dose rp2d.in the phase ii study, we will evaluate the safety and efficacy of the combination regimen.

this study was a single-arm, open, multicenter phase i/ii clinical study. an estimated 87 to 96 patients with relapsed or refractory ptcl will be enrolled. this program is divided into two parts: the phase i study is expected to enroll 9 to 18 patients with relapsed or refractory ptcl who will be treated with mitoxantrone hydrochloride liposome injection combined with chidamide.the phase ii study is expected to enroll 78 patients.

Eligibility criteria:
inclusion criteria: * patients participated voluntarily and signed informed consent； * ptcl confirmed by histopathology； * there must be at least one evaluable or measurable lesion that meets lugano2014 criteria； * the ecog score is 0 to 1； * anc≥1.5×10\*9/l，plt≥75 × 10\*9/l；hb≥80 g/l；tbil≤1.5uln；alt or ast≤2.5 uln； scr≤1.5uln； * use contraception during treatment and for one year after the end of treatment. exclusion criteria: * patients with central nervous system (cns) involvement and/or hemophagocytic syndrome； * the estimated survival time is less than 6 months； * history of allergy to anthracyclines or liposomes; previous recipients of mitoxantrone or mitoxantrone liposome;previous treatment with doxorubicin or other anthracyclines had a cumulative dose of doxorubicin \> 360 mg/m2（for other anthracyclines, 1 mg of doxorubicin is equivalent to 2 mg of epirubicin, and the maximum cumulative dose of liposomal doxorubicin is 2460mg/m2）； * the use of chidamide is contraindicated; * impaired heart function or significant heart disease; * hepatitis b, hepatitis c active stage infection; * had undergone major surgery within 4 to 6 weeks prior or expected to undergo major surgery during the study; * severe infection; * poorly controlled high blood pressure or diabetes; * a history of active visceral bleeding within the previous 3 months * a history of malignancy within five years; * history of mental illness; * a history of substance abuse or dependence; * pregnant or lactating woman; * the investigators did not consider it appropriate to participate in this study.
evaluation of neoadjuvant therapy efficacy and postoperative pathological indicators in esophageal cancer using ct and multimodal mri

Conditions: Esophageal Cancer; Neoadjuvant Therapy

Summary: this study aims to predict the efficacy of different types of neoadjuvant therapy and related postoperative pathological indicators in patients with esophageal cancer based on imaging parameters from ct and multimodal mri, as well as clinical indicators collected before and after neoadjuvant treatment.


Eligibility criteria:
inclusion criteria: 1. consecutive patients with histopathological diagnosis of esophageal cancer. 2. patients underwent neoadjuvant therapy before radical surgery for esophageal cancer: neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, neoadjuvant chemotherapy plus immunotherapy, neoadjuvant chemoradiotherapy plus immunotherapy. 3. all patients underwent ct and multimodal mri examinations before and after neoadjuvant therapy. 4. the preoperative clinical data and postoperative pathological data are complete. exclusion criteria: 1. patients with other primary malignant tumors or previous anti-tumor treatment. 2. ct and mri images with poor quality.